P53 codon 72 polymorphism and liver cancer susceptibility: A meta-analysis of epidemiologic studies

World Journal of Gastroenterology

Volumn 17, Issue 9, 2011, Pages 1211-1218

  Chen, Xi ^a   Liu, Fei ^a   Li, Bo ^a   Wei, Yong Gang ^a   Yan, Lv Nan ^a   Wen, Tian Fu ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Gene polymorphism; Liver cancer; Meta analysis; P53 codon 72

Indexed keywords

ARGININE; PROTEIN P53;

ADULT; ARTICLE; ASIAN; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CHRONIC HEPATITIS; CODON; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENDER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC);

EID: 79955941159     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i9.1211     Document Type: Article

References (58)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence- SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission
3. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santaquilani M. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-783
4. Tang ZY. Hepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-454
5. Zhu ZZ, Cong WM. [Roles of hepatitis B virus and hepatitis C virus in hepato-carcinogenesis]. Zhonghua Ganzangbing Zazhi 2003; 11: 574-576
6. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, Trichopoulos D, Stuver SO. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000; 85: 498-502
7. Chen CJ, Wang LY, Lu SN, Wu MH, You SL, Zhang YJ, Wang LW, Santella RM. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996; 24: 38-42
8. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, Groopman JD, Gao YT, Henderson BE. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943-946
9. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, Wogan GN, Groopman JD. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3: 3-10
10. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. TP53 and liver carcinogenesis. Hum Mutat 2003; 21: 201-216
11. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878
12. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988; 70: 245-252
13. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 357-365
14. Shepherd T, Tolbert D, Benedetti J, Macdonald J, Stemmermann G, Wiest J, DeVoe G, Miller MA, Wang J, Noffsinger A, Fenoglio-Preiser C. Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology 2000; 118: 1039-1044
15. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003; 18: 377-385
16. Lee JM, Shun CT, Wu MT, Chen YY, Yang SY, Hung HI, Chen JS, Hsu HH, Huang PM, Kuo SW, Lee YC. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat Res 2006; 594: 181-188
17. Hiyama T, Tanaka S, Kitadai Y, Ito M, Sumii M, Yoshihara M, Shimamoto F, Haruma K, Chayama K. p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer 2002; 100: 304-308
18. Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, Fuchs CS, Giovannucci EL, Hunter DJ. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 2006; 119: 1863-1868
19. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimäki A, von Smitten K, Aittomäki K, Heikkilä P, Blomqvist C, Nevanlinna H. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005; 11: 5098-5103
20. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002; 179: 175-183
21. Koushik A, Platt RW, Franco EL. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 2004; 13: 11-22
22. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 4.2.6. (updated September 2006). Chichester, UK: John Wiley & Sons, Ltd., 2006
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
24. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748
25. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
27. Zhu ZZ, Liu B, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu GS. Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. J Zhejiang Univ Sci B 2008; 9: 847-852
28. Etienne-Grimaldi MC, Formento JL, Francoual M, François E, Formento P, Renée N, Laurent-Puig P, Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz JF, Milano G. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008; 14: 4830-4835
29. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, Park JY, Myoung SM, Kim do Y, Chon CY, Han KH. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008; 29: 1192-1196
30. Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El Kihal L, Afifi R, Hassar M, Pineau P, Benjelloun S. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res 2007; 37: 748-754
31. Zhu ZZ, Cong WM, Zhu GS, Liu SF, Xian ZH, Wu WQ, Zhang XZ, Wang YH, Wu MC. [Association of p53 codon 72 polymorphism with genetic susceptibility to hepatocellular carcinoma in Chinese population]. Zhonghua Yixue Yichuanxue Zazhi 2005; 22: 632-635
32. Zhu ZZ, Cong WM, Liu SF, Xian ZH, Wu WQ, Wu MC, Gao B, Hou LF, Zhu GS. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett 2005; 229: 77-83
33. Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. [p53 gene codon 72 polymorphism and genetic susceptibility to hepatocellular carcinoma in Chinese population]. Zhonghua Yixue Zazhi 2005; 85: 76-79
34. Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 2005; 11: 289-292
35. Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU, De Silvestri A, Silini EM. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett 2004; 208: 75-79
36. Anzola M, Cuevas N, López-Martínez M, Saiz A, Burgos JJ, de Pancorbo MM. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 2003; 193: 199-205
37. Chen WC, Tsai FJ, Wu JY, Wu HC, Lu HF, Li CW. Distribu-tions of p53 codon 72 polymorphism in bladder cancer--proline form is prominent in invasive tumor. Urol Res 2000; 28: 293-296
38. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 1999; 29: 697-702
39. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-278
40. Ogimoto I, Shibata A, Kurozawa Y, Nose T, Yoshimura T, Suzuki H, Iwai N, Sakata R, Fujita Y, Ichikawa S, Fukuda K, Tamakoshi A. Risk of death due to hepatocellular carcinoma among drinkers and ex-drinkers. Univariate analysis of JACC study data. Kurume Med J 2004; 51: 59-70
41. Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Cogliano V. Carcinogenicity of alcoholic beverages. Lancet Oncol 2007; 8: 292-293
42. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum 2002; 82: 1-556
43. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004; 83: 1-1438
44. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227-3230
45. Feo F, Frau M, Tomasi ML, Brozzetti S, Pascale RM. Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma. Exp Biol Med (Maywood) 2009; 234: 726-736
46. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010; 52: 252-257
47. Shih WL, Yu MW, Chen PJ, Wu TW, Lin CL, Liu CJ, Lin SM, Tai DI, Lee SD, Liaw YF. Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study. Eur J Hum Genet 2009; 17: 1250-1259
48. Ezzikouri S, El Feydi AE, Benazzouz M, Afifi R, El Kihal L, Hassar M, Akil A, Pineau P, Benjelloun S. Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect Genet Evol 2009; 9: 877-881
49. Kim YJ, Lee HS. [Genetic epidemiological study on single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic HBV infection]. Korean J Hepatol 2009; 15: 7-14
50. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29: 306-309
51. Munafò M. Replication validity of genetic association studies of smoking behavior: what can meta-analytic techniques offer? Nicotine Tob Res 2004; 6: 381-382
52. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 2006; 38: 1133-1141
53. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004; 108: 196-199
54. Själander A, Birgander R, Kivelä A, Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 1995; 45: 144-149
55. Thomas DC, Witte JS. Point: population stratification: a problem for case-control studies of candidate-gene associations? Cancer Epidemiol Biomarkers Prev 2002; 11: 505-512
56. Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz D, Brockmöller J, Clapper ML, Daly A, Dolzan V, Ford J, Gaspari L, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Ingelman-Sundberg M, Kalina I, Kihara M, Kremers P, Le Marchand L, London SJ, Nazar-Stewart V, Onon-Kihara M, Rannug A, Romkes M, Ryberg D, Seidegard J, Shields P, Strange RC, Stücker I, To-Figueras J, Brennan P, Taioli E. Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis 2002; 23: 1343-1350
57. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-1133
58. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174